Phelpsbeard9429

Annexin V/PI staining showed that the percentage of the apoptotic OVCAR-3 cells increased from 2.15 in control to 45.24% at 60 µM concentration of Juglone. The induction of apoptosis in the OVCAR-3 cells was also accompanied with activation caspase-3, upregulation of Bax and downregulation of Bcl-2. Juglone was also found to cause an upsurge in the ROS levels in the OVCAR-3 cells. Cell cycle analysis showed that Juglone caused accumulation of the OVCAR-3 cells in the G2/M phase of the cell cycle triggering G2/M cell cycle arrest. Wound healing assay and transwell assay showed that Juglone suppressed the migration as well as the invasion of the OVCAR-3 cells, suggestive of the antimetastatic potential of this molecule. Conclusions Juglone may prove advantageous in ovarian cancer treatment.Purpose To explore the efficacy and safety of neoadjuvant chemotherapy (NAC) combined with cytoreductive surgery (CRS) and postoperative intraperitoneal hyperthermic chemotherapy (IPHC) in the treatment of advanced ovarian cancer. Methods 132 patients with advanced ovarian cancer admitted to our hospital from May 2013 to May 2016 were enrolled and randomly divided into control group (n=44), IPHC group (n=44) and NAC+IPHC group (n=44). The patients in the control group underwent CRS and postoperative TP chemotherapy (iv. drip of paclitaxel + peritoneal perfusion of cisplatin), those in IPHC group underwent the CRS and postoperative IPHC+TP chemotherapy, and those in the NAC+IPHC group received two cycles of preoperative NAC and postoperative IPHC+TP chemotherapy. The surgery indexes (operation time, amount of intraoperative bleeding, diameter of tumor and number of metastatic foci) were recorded. The clinical effective rate, changes in levels of serum tumor markers and adverse reactions were evaluated. Moreoverkably lower than in control group, and the median progression-free survival in NAC+IPHC group and IPHC group was remarkably longer than in control group, while it had no significant difference between NAC+IPHC group and IPHC group. The median overall survival had no statistically significant differences among the three groups. Conclusions NAC combined with IPHC can significantly reduce the perioperative risk, increase the optimal cytoreduction rate and raise the clinical effective rate of CRS in the treatment of advanced ovarian cancer. Moreover, patients have good tolerance, and both tumor progression and survival of patients are significantly improved.Purpose The purpose of this study was to compare the short- and long-term outcomes of laparoscopic surgery in elderly and middle-aged patients with clinical stage I endometrial cancer. Methods The clinical and follow-up data of 173 patients who were admitted to our hospital due to clinical stage I endometrial cancer and underwent laparoscopic surgery between January 2010 and December 2017 were retrospectively analyzed. The short- and long-term outcomes (including tumor recurrence, disease-free survival rate, and overall survival rate) of the elderly group (≥ 70 years, 69 patients) and the middle-aged group (50-69 years, 104 patients) were compared. Results In terms of preoperative general data comparison, only the Charlson comorbidity index and American Society of Anesthesiologists (ASA) score were higher in the elderly group than in the middle-aged group; differences in the remaining preoperative data were not statistically significant. Differences in general data, such as the operation time, proportion of patients that underwent lymphadenectomy, intraoperative blood loss, incidence and severity of postoperative 30-day complications, and pathological results were not statistically significant between the two groups. Long-term follow-up results showed that the two groups had similar tumor recurrence rates, as well as similar overall and disease-free survival rates. Multivariate analysis indicated that age was not an independent predictor for either overall or disease-free survival. Conclusions The use of laparoscopic surgery for elderly patients with clinical stage I endometrial cancer can achieve short- and long-term outcomes similar to those of middle-aged patients. Advanced age is not a contraindication to laparoscopic surgery.Purpose To investigate the influence of neoadjuvant chemotherapy on the efficacy, clinical indicators, prognosis and neutrophil/lymphocyte ratio (NLR) of stage IB2-IIB cervical cancer. Methods 120 cervical cancer patients were selected and randomly divided into the control group (n=60) and the observation group (n=60). The patients in the observation group were treated with neoadjuvant chemotherapy combined with surgery, while those in the control group received treatment with surgery alone. The serum tumor markers [matrix metalloproteinase-9 (MMP-9), carcino-embryonic antigen (CEA) and cancer antigen 125 (CA-125)], immunoglobulins (Igs) (IgA and IgM), T-lymphocyte subsets [cluster of differentiation (CD) 4+, CD8+ and CD4+/CD8+], NLR, quality of life, change in cancer-related fatigue degree and clinical efficacy were compared before and after treatment between the two groups. Results The levels of MMP-9, CEA, CA-125, NLR, IgA, IgM, CD4+ CD8+, CD4+/CD8+ and Cancer Fatigue Scale (CFS) were decreased, while the World Health Organization Quality of Life Scale Brief (WHOQOL-BREF) score was increased in both groups after treatment, and the observation group exhibited more apparent changes in those levels than the control group (p less then 0.05). Cytoskeletal Signaling modulator The effective rate was higher, but the incidence rates of postoperative lymphatic metastasis, vascular invasion, parametrial invasion and positive margin were lower in the observation group than those in the control group (p less then 0.05). The observation group had longer survival time than the control group (p less then 0.05). Conclusion Neoadjuvant chemotherapy can effectively lower the levels of serum tumor markers and NLR, reduce the metastasis rate of cancer cells and the degree of cancer-related fatigue after operation, improve the quality of life and prolong the survival time.Purpose Ovarian cancer (OC) is perhaps the most difficult problem in gynaecologic oncology; in particular the drug-resistant ovarian cancer remains a challenge for the clinicians. Therefore there is a pressing need for novel and effective chemotherapeutic agents against OC. The main objective of the current research work was to study the anticancer effects of a naturally occurring triterpene acid, ursolic acid, against SKOV-3 OC cells. Its effects on reactive oxygen species (ROS)-mediated apoptosis were also studied along with cell cycle phase distribution and PI3K/AKT signalling pathway. Methods Cell proliferation was checked by CCK8 cell viability assay. Apoptosis-related studies were examined by fluorescent microscopy using acridine orange (AO)/ethidium bromide (EB) and DAPI staining as well as flow cytometry using annexin V/propidium iodide (PI) assay. Further, western blot assay was used to study effects of ursolic acid on the apoptosis-related protein expressions including Bax, Bcl-2 as well as PI3K/AKT signalling pathway.